Journal article
A Phase II Study of Leuprolide in Advanced/Recurrent Endometrial Cancer
Abstract
In order to determine the efficacy and toxicity of the gonadotrophin-releasing hormone agonist Leuprolide in the management of patients with recurrent or metastatic endometrial cancer, we performed a phase II study. Patients were included if there was clinical or radiological documentation of bidimensionally measurable recurrent or metastatic endometrial cancer that was deemed incurable. Treatment was 7.5 mg i.m. every 28 days, and was to …
Authors
Covens A; Thomas G; Shaw P; Ackerman I; Osborne R; Lukka H; Carey M; Franssen E; Roche K
Journal
Gynecologic Oncology, Vol. 64, No. 1, pp. 126–129
Publisher
Elsevier
Publication Date
January 1997
DOI
10.1006/gyno.1996.4544
ISSN
0090-8258